Compare Agora Inc (API) vs Novavax Inc (NVAX) Price & Performance

Agora, Inc. (API) trades at $4.22, down 2.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue above guidance and its sixth consecutive quarter of GAAP profitability, with net income of $9.53 million in 2025. Recent news highlights management share purchases and a partnership with thymia for real-time health intelligence.

Outlook remains positive with analyst consensus at 60% buy ratings, supported by strong cash flow growth and a low P/B of 0.64. Key risks include competitive pressures in conversational AI and potential volatility from high short interest growth of 30.3% as of March 31, 2026 (Defense World).

Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.

The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.